Pharsight, Tripos merger on track to close Friday

By Lisa Kerner

Charlotte, N.C., Oct. 27 - Pharsight Corp. stockholders approved the company's acquisition by Tripos, Inc. at a special meeting on Monday.

The acquisition is now expected to close on Friday, after which Pharsight will cease trading on the Nasdaq Capital Market, a Pharsight news release said.

It was previously reported that Tripos agreed to acquire Pharsight, a Mountain View, Calif., pharmaceutical software company, for $5.50 per share, or $57 million in cash.

Tripos provides drug discovery informatics products and services. The company is located in St. Louis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.